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Abstract: The drug efflux activity of P-glycoprotein (P-gp, a product of the mdr1 gene, 
ABCB1 member of ABC transporter family) represents a mechanism by which tumor cells 
escape death induced by chemotherapeutics. In this study, we investigated the mechanisms 
involved  in  the  effects  of  pentoxifylline  (PTX)  on  P-gp-mediated  multidrug  resistance 
(MDR)  in  mouse  leukemia  L1210/VCR  cells.  Parental  sensitive  mouse  leukemia  cells 
L1210,  and  multidrug-resistant  cells,  L1210/VCR,  which  are  characterized  by  the 
overexpression of P-gp, were used as experimental models. The cells were exposed to  
100 μmol/L PTX in the presence or absence of 1.2 μmol/L vincristine (VCR). Western blot 
analysis indicated a downregulation of P-gp protein expression when multidrug-resistant 
L1210/VCR  cells  were  exposed  to  PTX.  The  effects  of  PTX  on  the  sensitization  of 
L1210/VCR cells to VCR correlate with the stimulation of apoptosis detected by Annexin 
V/propidium iodide apoptosis necrosis kit and proteolytic activation of both caspase-3 and 
caspase-9 monitored by Western blot analysis. Higher release of matrix metalloproteinases 
(MMPs), especially MMP-2, which could be attenuated by PTX, was found in L1210/VCR 
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than in L1210 cells by gelatin zymography in electrophoretic gel. Exposure of resistant 
cells to PTX increased the content of phosphorylated Akt kinase. In contrast, the presence 
of VCR eliminated the effects of PTX on Akt kinase phosphorylation. Taken together, we 
conclude  that  PTX  induces  the  sensitization  of  multidrug-resistant  cells  to  VCR  via 
downregulation of P-gp, stimulation of apoptosis and reduction of MMPs released from 
drug-resistant L1210/VCR cells. These facts bring new insights into the mechanisms of 
PTX action on cancer cells. 
Keywords:  pentoxifylline;  P-glycoprotein;  multidrug  resistance;  apoptosis;  matrix 
metalloproteinases; caspases 
 
1. Introduction 
A major problem in cancer chemotherapy is the development of a multidrug resistance (MDR) 
phenotype in cancer cells. The drug efflux activity of P-glycoprotein (P-gp, a product of the mdr1 gene 
and an ABCB1 member of the ABC transporter family) represents a mechanism by which tumor cells 
escape death induced by chemotherapeutic agents, resulting in the development of MDR in cancer 
cells  and  causing  them  to  become  insensitive  to  a  range  of  different  cytostatic  drugs  [1,2]. 
Pentoxifylline (PTX) is a methylxanthine well-known for its roles as a phosphodiesterase inhibitor,  
a  ligand  of  adenosine  receptors,  a  modulator  of  the  ryanodine  Ca
2+-release  channel  of  the 
sarco(endo)plasmic reticulum, and a downregulator of TNF-α [3–6]. Additional reports also suggest 
that PTX administration might increase the effectiveness of antitumor chemotherapy [7,8], and our 
previous studies demonstrated that PTX induced the reversal of vincristine (VCR) and/or adriamycin 
resistance in P-gp-positive L1210/VCR (P-gp positive cell variant of L1210 cells were obtained by 
selection with VCR) mouse leukemia cells [9,10]. However, the mechanism of PTX action on drug 
resistance of cancer cells still remains unclear. 
P-gp-positive  L1210/VCR  mouse  leukemia  cells  were  found  to  be  defective  in  drug-induced 
apoptosis, even for drugs that are not substrates of P-gp [11]. Recently, sensitization of cervical cancer 
cells to adriamycin by PTX was found to be associated with more pronounced apoptosis [12]. Here, we 
tested the hypothesis that PTX restores the sensitivity of L1210/VCR cells to VCR due to a decrease in 
P-gp protein and that this effect is associated with a stimulation of apoptosis. We described the MDR 
reversal effect of LY294,006, (an inhibitor of PI3K/Akt kinase pathway) in L1210/VCR cells [13]. 
Pentoxyfilline was described to diminish activation of Akt kinase induced by chronic common bile 
duct  ligation  lung  [14].  Therefore,  we  tested  the  hypothesis  if  PTX  effect  on  MDR  reversal  in 
L1210/VCR cells is associated with modulation of Akt kinase levels or activation. PTX was also found 
to inhibit the proliferation of B16F10 melanoma cells by inhibiting cell adhesion and secretion of 
matrix  metalloproteinases  (MMPs)  [15].  Another  study  reported  that  lung  carcinoma  cell  variants 
obtained  by  selection  with  anticancer  drugs  showed  enhanced  invasive  abilities  through  the 
upregulation of MMPs [16]. In order to determine the role of MMPs in the PTX-induced effects on 
drug-resistant L1210/VCR cells, we examined the influence of PTX on these enzymes. Current paper 
is aiming to study if exist any relation between PTX induced P-gp downregulation in L1210/VCR cells Int. J. Mol. Sci. 2012, 13                       
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and the effect of PTX on: (i) apoptosis induced by vincristine detected by annexin V binding and 
caspases activation; (ii) Akt kinase levels and activation and (iii) MMPs release. 
2. Results and Discussion 
2.1. Results 
2.1.1. Pentoxifylline Reduces P-glycoprotein Protein Levels 
P-gp in membrane fraction isolated from P-gp-positive L1210/VCR cells was detected by Western 
blot analysis using a c219 antibody (Figure 1). 
Figure 1. Reduction of P-glycoprotein (P-gp) protein levels by pentoxifylline (PTX). P-gp 
protein  levels  were  analyzed  L1210  and  L1210/VCR  cells  treated  with  1.2  μmol/L 
vincristine (VCR) and/or 100 μmol/L PTX for 24 h. The protein levels of P-glycoprotein 
and  GAPDH  (housekeeper)  were  determined  by  Western  blot  analysis  using  specific 
antibodies. Blots of three independent experiments were quantified and obtained data were 
evaluated by Student’s t test. Data represent means ±  SD. * Different from control (without 
drugs) at significance level p < 0.01. 
 
The parental cells did not contain any detectable amount of P-gp under the applied experimental 
conditions. Cultivation of resistant cells in the presence of 1.2 μmol/L VCR induced only a slight  
(if any) increase in P-gp protein levels. VCR at this concentration induced massive cell damage in 
L1210  cells  but  did  not  influence  the  survival  of  L1210/VCR  cells  [17].  In  contrast,  PTX  at  a 
concentration of 100 μmol/L induced a strong decrease in P-gp protein levels in L1210/VCR cells. 
PTX alone at this concentration did not influence the viability of either L1210 or L1210/VCR cell lines 
but induced a massive reversal of VCR resistance in L1210/VCR cells [10,18,19]. 
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2.1.2. Drug Reversal Effects of Pentoxifylline Are Associated with the Stimulation of Apoptosis 
The presence of VCR alone in the cultivation medium induced a massive increase in the percentage 
of apoptotic cells in sensitive L1210 cells but not in resistant L1210/VCR cells (Figure 2). This could 
be detected as early (cells labelled with annexin V only) and late (cells labelled by both annexin V and 
propidium  iodide)  apoptosis  and  was  determined  by  flow  cytometry  using  the  Annexin  V-FITC 
Apoptosis  detection  kit.  However,  the  presence  of  both  VCR  and  PTX  induced  an  increase  in  
the  number  of  early  and  late  apoptotic  L1210/VCR  cells  (Figure  2).  This  may  be  ascribed  to  a  
PTX-induced reversal of VCR resistance in L1210/VCR cells, as described previously [10,18,19], 
because PTX alone induced only slight changes in the apoptotic progression of L1210 or L1210/VCR 
cells. However, PTX alone induced an increase in cleaved/activated caspase-9 (an enzyme known to 
be active in apoptosis) (Figure 3) corresponding to a decrease in the non-cleaved form of this enzyme 
in P-gp-positive L1210/VCR cells. Activation of this enzyme under the influence of PTX was not 
observed in sensitive L1210 cells. When investigating the effects of PTX on caspase-3 (an enzyme 
downstream of caspase-9), we did not find significant differences in the levels of inactive zymogen in 
either sensitive L1210 or resistant L1210/VCR cells (Figure 3). VCR induced an increase in the levels 
of both cleaved caspase-3 and caspase-9 in sensitive cells. These effects of VCR on caspase activation 
were  not  observed  in  the  resistant  cell  variant.  However,  combined  treatment  of  P-gp-positive 
L1210/VCR cells with both PTX and VCR induced a more pronounced proteolytic activation of both 
caspase-3 and caspase-9. 
Figure 2. The effects of VCR and PTX on apoptosis induction in sensitive (L1210) and 
multidrug-resistant (L1210/VCR) cells. Cells were exposed to VCR (1.2 μmol/L) and/or 
PTX (100 μmol/L) for 24 h. Induction of apoptosis was detected by flow cytometry using 
an Annexin V-FITC Apoptos1is detection kit. Staining of cells by annexin V-FITC or 
propidium iodide was determined by measuring the fluorescence of cells using a Coulter 
Epics  Altra  flow  cytometer.  The  proportions  of  cells  stained  with  annexin  V-FITC  
(early  apoptotic  cells),  cells  with  both  annexin  V-FITC  and  propidium  iodide  (late 
apoptotic/necrotic cells) and unstained cells (normal cells) are summarized. Data represent 
means ±  SD from free independent experiments. * Different from control (without drugs) 
at significance levels p < 0.01. 
 Int. J. Mol. Sci. 2012, 13                       
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Figure 3. Effect of VCR and PTX treatment on caspase-3 and caspase-9. The sensitive 
L1210 and resistant L1210/VCR cells were treated with VCR (1.2 μmol/L) and/or PTX 
(100  μmol/L)  for  24  h.  The  protein  levels  of  full-length  and  cleaved  caspase-3  and  
caspase-9 were determined by Western blot analysis using specific antibodies. Blots of 
three  independent  experiments  were  quantified  and  obtained  data  were  evaluated  by 
Student’s  t  test.  *  And  **  different  from  control  (without  drugs)  at  significance  level  
p < 0.01 and p < 0.05, respectively. 
 
2.1.3. Pentoxifylline Influences the Activation of Akt Kinase in Resistant L1210/VCR Cells 
Resistant  variant  of  L1210  cells  contains  higher  content  of  Akt  kinase  protein  than  sensitive 
parental cells (Figure 4). The incubation of both sensitive L1210 and resistant L1210/VCR cells in the 
presence of VCR and/or PTX for 24 h did not influence the protein levels of Akt kinase (Figure 4). Akt 
kinase activity is stimulated via phosphorylation of Ser473 by upstream protein kinases [20]. Therefore, 
the  amounts  of  Ser473-phosphorylated  Akt  kinase  were  investigated  using  a  specifically  reacting 
antibody. Sensitive and resistant cells did not contain any detectable Akt kinase phosphorylated  on 
Ser473 at basal conditions or in the presence of VCR. In contrast to sensitive L1210 cells, exposure of 
resistant L1210/VCR cells to 100 μmol/L PTX for 24 h markedly increased the phosphorylation of Akt 
kinase (Figure 4). Int. J. Mol. Sci. 2012, 13                       
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Figure 4. Effect of VCR and PTX treatment on Akt kinase protein expression and specific 
phosphorylation. The sensitive L1210 and resistant L1210/VCR cells were treated with 
100 μmol/L PTX and/or 1.2 μmol/L VCR for 24 h, Akt kinase protein expression and its 
specific  fosforylation  (on  Ser  473)  were  determined  by  Western  blot  analysis  using  a 
specific antibodies. Blots of three independent experiments were quantified and obtained 
data  were  evaluated  by  Student’s  t  test.  *  Different  from  control  (without  drugs)  at 
significance level p < 0.01. 
 
However, presence of VCR during treatment of resistant cells with PTX induced depression of Akt 
kinase phosphorylation. 
2.1.4. Pentoxifylline Affects the Release of Matrix Metalloproteinases from L1210/VCR Cells 
The activities of matrix metalloproteinases released from sensitive L1210 and resistant L1210/VCR 
cells into external (conditioned) medium were analyzed by gelatin zymography. Recombinant, active 
MMP-2 was used as a positive control to identify the active 63 kDa MMP-2 form. Pro-MMP-2 and 
MMP-9 were identified using fetal bovine serum containing predominantly these forms of both MMPs. 
Gelatin  zymography  of  the  concentrated  conditioned  media  revealed  gelatinolytic  activities 
corresponding to MMP-2 and MMP-9 in samples from L1210/VCR cells but not from L1210 cells 
(Figure 5A). This indicated an increased secretion of both enzymes from the P-gp-positive cell variant. 
The zymogram for L1210/VCR cells showed the presence of gelatinolytic activities at 92 kDa and  
72 kDa, which represent  the  latent forms  of both  MMP-9 and  MMP-2, respectively (Figure 5A). 
However, gelatinolytic activities were not detected at 88 and 63 kDa, which represent the cleaved 
forms of MMP-9 and MMP-2, respectively. The increased secretion of matrix metalloproteinases from 
L1210/VCR cells could be attenuated by PTX but not by VCR (Figure 5A). 
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Figure 5. Effects of VCR and PTX treatment on the secretion of matrix metalloproteinases 
from  sensitive  L1210  and  resistant  L1210/VCR  cells  into  the  external  medium.  
(A) Zymogram showing the activities of matrix metalloproteinases analyzed using gelatin 
zymography; (B) The protein expression of secreted MMP-2 was analyzed by Western blot 
analysis  using  a  specific  antibody  that  reacts  with  both  the  72  and  63  kDa  forms  of  
MMP-2.  Zymograms  and  blots  of  three  independent  experiments  were  quantified  and 
obtained data were evaluated by Student’s t test. * Different from control (without drugs) 
at significance level p < 0.01. 
 
 
We  detected  the  presence  of  MMP-2  by  Western  blot  analysis,  using  a  specific  antibody  that 
recognized both the latent (72 kDa) and cleaved form (63 kDa) of MMP-2 in the conditioned medium 
obtained after incubation of L1210/VCR (Figure 5B). In contrast, conditioned medium obtained after 
incubation of L1210 cells did not contains detectable amounts of MMP2 forms (Figure 5B). Combine 
treatment of L1210/VCR cells by PTX and VCR decreased content of both forms of MMP-2. 
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2.2. Discussion 
Previously,  we  have  described  a  reduction  in  P-gp  mRNA  in  L1210/VCR  cells  after  PTX  
treatment  [9,19].  This  P-gp  downregulation  observed  in  L1210/VCR  cells  was  assumed  to  be 
responsible for the reversal of the adriamycin or VCR resistance in this cell model [9,19] and the 
elevation  of  the  intracellular  concentrations  of  both  cytostatics.  The  ability  of  PTX  to  potentiate 
adriamycin toxicity was also described in chronic human myeloid leukemia cells and in P388 leukemia 
cells [21,22]. In the current paper, we demonstrated a decrease in P-gp protein expression after PTX 
treatment  (Figure  1).  This  effect  of  PTX  on  P-gp  cellular  expression  could  be  achieved  at  a  PTX 
concentration that did not induce significant cell damage to L1210 cells or its MDR variants [9,10,18,19]. 
Interestingly,  in  contrast  to  PTX,  which  induced  a  reversal  of  the  P-gp  mediated  MDR  in 
L1210/VCR  cells  [18],  other  xanthines,  such  as  caffeine  or  theophylline,  did  not  induce  such  an  
effect [10]. Moreover, caffeine was not able to alter mdr1 mRNA levels [19]. The fact that both the 
caffeine and theophylline are effective in the generally known pharmacological roles of xanthines 
(described in the introduction) but not in the modulation of P-gp mediated MDR fails to satisfactorily 
explain  the  VCR-induced  reversal  of  MDR  on  the  basis  of  common  pharmacological  effects  of 
xanthines. Neither PTX nor its major oxidative metabolites influenced the ATPase activity measured 
in  membrane  vesicles  isolated  from  Sf9  insect  cells  infected  with  a  baculovirus  containing  the 
respective genes for ABC transporters such as P-gp [23]. 
This suggests that PTX does not induce its effects on P-gp-mediated MDR via alteration of ATP 
hydrolysis.  Instead,  PTX  was  found  to  sensitize  the  multidrug-resistant  mouse  leukemia  cell  line 
L1210/VCR  to  VCR  by  stimulating  apoptosis.  Similarly  to  PTX,  LY294,002  was  also  found  to 
increase apoptosis induced by vincristine in this cell model [13]. However, in contrast to PTX that 
induces an elevation of Akt kinase activation (Figure 4) LY294,002, as PI3K/Akt kinase pathway 
inhibitor,  induced  opposite effect. Akt kinase is  believed to  play an antiapoptotic  role  [24].  Thus 
activation of Akt kinase induced by PTX (Figure 4) represents rather confusing result that have to be 
clarified by further study. Nevertheless, in the presence of PTX and VCR, i.e., in condition when 
apoptosis progression in L1210/VCR cells was observed (Figure 2), the Akt kinase phosphorylation 
was declined to the levels only slightly higher than in control (Figure 4). A dose-dependent increase in 
the  percentage  of  apoptotic  cells  after  PTX  treatment,  mediated  by  a  pathway  that  included 
cytochrome  c  release,  caspase-3  activation  and  PARP  cleavage,  was  also  documented  in  HuT-78  
cells [25]. These results suggest that the effect that PTX exerts on L1210/VCR cells is at least partially 
through PTX promotion of apoptosis. Mouse leukemia cells that developed MRD by overexpression of 
P-gp were found to also be cross-resistant to cisplatin, even though cisplatin is not a substrate of P-gp. 
These cells were found to be defective in cisplatin-induced initiation of apoptosis. This inability to 
enter apoptosis was associated with an imbalance between antiapoptotic and proapoptic proteins of the 
Bcl family [11]. The high expression levels of both P-gp and the antiapoptotic proto-oncogene Bcl-2 
were reported to be associated with in vitro resistance to chemotherapeutic agents and a poor clinical 
outcome  in  cases  of  acute  myeloid  leukemia  (AML)  [26]  and  in  cases  of  adults  who  have  acute 
lymphoblastic leukemia [27]. 
Cancer cell growth and dissemination may be influenced by matrix metalloproteinases, which are 
secreted extracellularly. Matrix metalloproteinases are key extracellular matrix-degrading enzymes. A Int. J. Mol. Sci. 2012, 13                       
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close association between the expression or activity of distinct matrix metalloproteinases and both 
tumor cell invasion and metastasis has been described [28]. Resistance of AML cells to anticancer 
drugs was described to be associated with increased activity and expression of MMP-2, which induced 
an enhancement in their invasivity [29]. This resistance of AML cells to anticancer drugs was also 
found to lead to a lack of drug-induced cell death, such as apoptosis. 
An increased release of matrix metalloproteinases, which could be attenuated by PTX, was found in 
L1210/VCR  cells,  compared  to  parental  L1210  cells.  The  doubling  time  of  L1210/VCR  cells, 
estimated to be 12 h, was shorter than the doubling time of 22 h observed for L1210 cells (data not 
shown). Thus, resistant cells could be considered as those with a higher proliferation rate. A direct 
connection  between  elevated  activity  of  metalloproteinases  in  the  extracellular  matrix  and  cell 
proliferation was recently documented based on the release of extracellular matrix membrane-anchored 
growth factors [30]. This phenomenon may be related to a higher invasive ability of cells through 
upregulation of MMPs [16]. PTX was also found to inhibit proliferation of the melanoma B16F10 
cells by inhibiting cell adhesion and secretion of matrix metalloproteinases [15]. 
Pentoxifylline is a substance which improves the sensitivity of several neoplastic cells to a large 
group of drugs that includes both substrates and nonsubstrates of P-gp [8,19,31]. In clinical conditions, 
PTX was described to prevent side-effects induced by irradiation during radiotherapy of breast cancer [32]. 
Our  results  indicate  that  this  substance  may  also  be  useful  in  potentiating  anticancer  drugs’ 
effectiveness. However, this aspect has to be verified in clinical conditions. 
3. Experimental Section 
3.1. Materials 
The primary antibodies used were the following: anti-Akt kinase, anti-MMP-2, anti-GAPDH (all 
from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-phospho-Akt kinase (reacts with  
Ser473-phosphorylated Akt kinase), anti-caspase-3, anti-cleaved caspase-3, anti-caspase-9, and anti-
cleaved caspase-9 (all from Cell Signaling Technology Inc., Danvers, MA, USA). Pentoxifylline was 
obtained  from  Zentiva  (formerly  Slovakofarma,  Hlohovec,  Slovakia).  Vincristine  was  supplied  by 
Gedeon Richter (Budapest, Hungary). 
3.2. Cell Culture and Exposure of Cells to Pentoxifylline and Vincristine 
Parental sensitive mouse leukemia cell line L1210 and multidrug-resistant cell line L1210/VCR, 
which was obtained by long-term adaptation of sensitive cells to VCR, were used as experimental 
models (additional details characterizing this cell line are described elsewhere [11,33]). Both sensitive 
and resistant cells were grown under baseline conditions in RPMI-1640 medium supplemented with  
4% fetal bovine serum in an incubator at 37 ° C in a 5% CO2—95% air atmosphere. The L1210/VCR 
were  cultured  long  term with  addition of VCR (1.2  μmol/L)  during each third passage.  Sensitive 
L1210 and resistant L1210/VCR cells were exposed to 100 μmol/L PTX in the presence or absence of 
1.2 μmol/L VCR for 24 h. These conditions were proved to be effective in P-gp transport activity and 
expression downregulation, in previous papers [9,19]. 
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3.3. Preparation of Cellular Protein Fractions and Western Blot Analysis 
After a cultivation period of 24 h, cells were centrifuged at 400 ×  g for 5 min, washed once with 
isotonic physiological solution and pelleted. To isolate the soluble protein fraction, pelleted cells were 
resuspended in ice-cold buffer containing 20 mmol/L Tris (pH 7.4), 1.0 mmol/L EGTA, 1.0 mmol/L DTT, 
0.1 mmol/L sodium orthovanadate, and 0.5 mmol/L PMSF. After homogenization with a Teflon pestle 
homogenizer, the homogenate was centrifuged at 14,000 ×  g for 30 min at 4 ° C. The supernatant was 
used for further analysis. Protein concentrations were determined according to the method of Bradford [34] 
using bovine serum albumin as a standard. Crude membrane fractions (used for P-gp determination) 
were  isolated  by  processing  pelleted  cells  according  to  manufacturer  recommendations  using  the 
ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, CA, USA). Proteins in these samples 
were assessed using the Lowry protocol modified for membrane proteins by Peters et al. [35]. 
For Western blot analysis, 30 μg of each of the proteins was separated on SDS-polyacrylamide gels 
under reducing conditions [36]. Routinely, 10% gels were used with exception of P-gp detection where 8% 
gels  were  used.  The  proteins  after  electrophoretic  separation  were  transferred  onto  nitrocellulose 
membranes, and after blocking of non-specific binding sites, the membranes were incubated overnight 
at 4 ° C with the corresponding specific primary antibody [37]. The corresponding peroxidase-labeled 
anti-rabbit  or  anti-mouse  immunoglobulins  (Cell  Signaling  Technology  Inc.,  Danvers,  MA,  USA) 
were  used  as  secondary  antibodies.  Peroxidase  reactions  were  detected  by  the  enhanced 
chemiluminescence  (ECL)  system  (GE  Healthcare,  Piscataway,  NJ,  USA,  formerly  Amersham 
Biosciences, UK). 
3.4. Detection of Apoptotic Cells by FACS Analysis 
Induction  of  apoptosis  was  detected  by  flow  cytometry  using  the  Annexin  V-FITC  Apoptosis 
detection kit (Sigma-Aldrich Corp., St. Louis, MO, USA). Sensitive or resistant cells in culture were 
preincubated in the absence or presence of VCR (1.2 μmol/L) and/or PTX (100 μmol/L) for 24 h. After 
this  incubation, cells  were  washed  twice  with PBS and  resuspended in  500  μL  of binding buffer  
(10  mmol/L  HEPES/NaOH,  pH  7.5  containing  140  mmol/L  NaCl  and  2.5  mmol/L  CaCl2)  at  a 
concentration of approximately 1 ×  10
6 cells/mL. Cell suspensions were added to plastic test tubes, and 
5 μL of annexin V-FITC (50 μg/mL) and 10 μL of propidium iodide (100 μg/mL) were added to each 
cell  suspension.  The  tubes  were  incubated  at  room  temperature  for  10  min,  following  which  the 
fluorescence of the cells was determined using a Coulter Epics Altra flow cytometer (Beckman Coulter, 
Inc., Fullerton, CA, USA) 
3.5. Effect of Pentoxifylline on the Release of Metalloproteinases from Sensitive L1210 and  
Drug-Resistant L1210/VCR Cells 
Sensitive L1210 and resistant L1210/VCR cells cultured in RPMI-1640 medium supplemented with 
4%  fetal  bovine  serum  were  centrifuged  at  400  ×   g  for  4  min,  washed  twice  with  serum-free  
RPMI-1640  medium  and  resuspended  in  serum-free  medium.  Cells  (5  ×   10
5  cells/mL)  were  then 
incubated in the absence of fetal bovine serum and exposed to 100 μmol/L PTX in the presence or 
absence of 1.2 μmol/L VCR. Conditioned medium was collected after 18 h, and cell-free supernatants Int. J. Mol. Sci. 2012, 13                       
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were obtained by centrifugation. For each sample, 5 mL of cell-free supernatant was dialyzed against 
20 mmol/L Tris-HCl buffer (pH 6.8), lyophilized and finally resuspended in 300 μL of 20 mmol/L 
Tris-HCl  buffer (pH 6.8).  To investigate the effects  of  PTX treatment  on  the  secretion  of matrix 
metalloproteinases from sensitive L1210 and resistant L1210/VCR cells, Western blot analysis with 
anti-MMP-2  antibody  or  gelatin  zymography  of  concentrated  conditioned  medium  samples  
was performed. 
3.6. Gelatin Zymography 
The samples of conditioned medium were mixed in a ratio of 1:1 with non-reducing Laemmli’s 
buffer and subjected to electrophoresis on 10% SDS-polyacrylamide gels co-polymerized with gelatin 
(final concentration of 2 g/L). After electrophoresis, gels were washed twice for 20 min each with  
50 mmol/L Tris-HCl buffer (pH 7.4), containing 2.5% Triton X-100, at 25 ° C. After washing, the gels 
were incubated overnight at 37 ° C in substrate (developing) buffer containing 50 mmol/L Tris-HCl 
buffer (pH  7.4),  10 mmol/L CaCl2  and  1.25%  Triton X-100. After  this  incubation, the gels were 
stained with 1% Coomassie Brilliant Blue G-250 dissolved in an aqueous solution containing 10% 
acetic acid and 40% methanol and then destained with an aqueous solution containing 10% acetic acid 
and 40% methanol. Gelatinolytic activities of MMP-2 and MMP-9 were detected as transparent bands 
against a dark blue background. Recombinant, active MMP-2 (Calbiochem, La Jolla, CA, USA) was 
used as a positive control. 
3.7. Statistical Analysis 
Data from three independent experiments were expressed as the mean ±  SD. Statistical significance 
was assessed by an unpaired Student’s t-test. 
4. Conclusions 
Taken together, obtained results support our hypothesis that PTX may restore the sensitivity of 
neoplastic  drug-resistant  L1210/VCR  cells  to  vincristine  via  the  downregulation  of  P-gp  protein 
expression. The PTX-induced restoration of L1210/VCR cells sensitivity to vincristine is associated 
with  apoptosis  induction  through  modulation  of  caspases  activation.  Further,  we  found  that  PTX 
influenced activation of Akt kinase. However, modulation of this kinase seems to be not directly 
involved  in  vincristine  resistance  reversal  induced  by  PTX  in  L1210/VCR  cells.  PTX-  induced 
improvement of vincristine cytotoxicity in L1210/VCR cells are also associated with modulation of 
extracellular release of MMPs. 
All these aspects would be considered when elucidating the beneficial effects of PTX on neoplastic 
cells treated with anticancer drugs. Moreover, the obtained data bring new insights into the possible 
mechanisms of PTX action on cancer cells. 
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